| 25.36 0.47 (1.89%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.81  |
1-year : | 45.6 |
| Resists | First : | 33.22 |
Second : | 39.04 |
| Pivot price | 26.13 |
|||
| Supports | First : | 23.81 | Second : | 19.81 |
| MAs | MA(5) : | 24.93 |
MA(20) : | 26.93 |
| MA(100) : | 32.77 |
MA(250) : | 33.17 |
|
| MACD | MACD : | -1.9 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 18 |
D(3) : | 10.7 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 43.15 | Low : | 23.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VKTX ] has closed above bottom band by 35.4%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.44 - 25.56 | 25.56 - 25.68 |
| Low: | 24.12 - 24.26 | 24.26 - 24.39 |
| Close: | 25.12 - 25.36 | 25.36 - 25.57 |
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Thu, 29 Oct 2026
Viking Therapeutics Q3 Earnings Call Highlights - Yahoo Finance
Wed, 28 Oct 2026
Viking Therapeutics (VKTX) Advances Obesity Pipeline, Raises $57 - GuruFocus
Wed, 28 Oct 2026
VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail - Yahoo Finance
Wed, 28 Oct 2026
VKTX: Four VK2735 Phase III studies advance, backed by $960M in quarter-end liquidity - TradingView
Wed, 28 Oct 2026
Viking Therapeutics (VKTX) Reports Q3 $183M Loss Amid Rising R&D Costs - GuruFocus
Wed, 28 Oct 2026
Viking Therapeutics falls on third quarter loss miss - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 60.4 (%) |
| Shares Short | 25,920 (K) |
| Shares Short P.Month | 22,190 (K) |
| EPS | -4.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.9 % |
| Return on Equity (ttm) | -88.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -418 (M) |
| Levered Free Cash Flow | -231 (M) |
| PE Ratio | -5.44 |
| PEG Ratio | 0 |
| Price to Book value | 7.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|